U.S. Online Retail and Ecommerce Stock News

In early February 2026, Pfizer reported mixed 2025 financial results, reaffirmed 2026 revenue guidance, highlighted progress in its GLP-1 obesity pipeline, secured FDA Priority Review to expand HYMPAVZI’s hemophilia indication, and joined the TrumpRx drug pricing platform with discounted access to more than 30 medicines. Together, these developments underscore how Pfizer is trying to offset patent expiries and waning COVID-19 revenues by building new specialty and obesity franchises while...

Dynatrace (DT) just posted its Q3 2026 scorecard with recent quarterly revenue running at about $493.8 million and Basic EPS of roughly $0.19, set against a trailing 12 month picture that includes Basic EPS of $1.69 and revenue of about $1.9 billion, plus earnings growth in the dataset of 210.1% over the past year. The company has seen revenue move from $399.2 million in Q1 2025 to $493.8 million in Q2 2026 and quarterly Basic EPS shift from $0.13 to $0.19 over the same period. Year long...

Waters (WAT) FY 2025 earnings snapshot Waters (WAT) reported Q3 FY 2025 revenue of US$799.9 million and basic EPS of US$2.50, with trailing 12 month EPS of US$10.91 on revenue of about US$3.1 billion. The company’s quarterly revenue rose from US$708.5 million in Q2 2024 to US$771.3 million in Q2 2025, and then to US$799.9 million in Q3 2025. Over the same periods, basic EPS moved from US$2.41 to US$2.47 and then to US$2.50, highlighting a story focused on consistent earnings and resilient...

This article examines whether Medline, at around US$47.37, is trading at fair value or something more compelling, and explores what the current price might be indicating. Over shorter time frames, the stock has returned 5.2% over the last week, 16.9% over the last 30 days and 16.6% year to date. These moves may have drawn the attention of investors who follow momentum and shifts in risk sentiment. Recent news about Medline has focused on its position in the healthcare space and how investors...

Trigger and recent performance snapshot Taiwan Semiconductor Manufacturing (NYSE:TSM) has attracted fresh attention after a period of strong share price movement, with the stock showing double digit returns over the past month and over the past 3 months. Investors considering that performance may also note annual revenue of US$3.81b and net income of US$1.72b, alongside a value score of 3 that can support basic screening approaches. See our latest analysis for Taiwan Semiconductor...

TG Therapeutics (TGTX) has been in focus after presenting new BRIUMVI data for relapsing multiple sclerosis at the ACTRIMS forum and launching a national MS awareness campaign with actress Christina Applegate. See our latest analysis for TG Therapeutics. At a share price of US$29.58, TG Therapeutics has seen recent momentum pick up, with a 1 month share price return of 3.9% following BRIUMVI data updates and the Christina Applegate MS awareness campaign. This compares with a 1 year total...

Why Brookfield Business Partners Stock Is Back on Investors’ Radar Brookfield Business Partners (NYSE:BBU) just paired its 2025 earnings release with a fresh share buyback update and an affirmed dividend plan tied to its upcoming corporate reorganization, drawing fresh attention from income focused investors. See our latest analysis for Brookfield Business Partners. The confirmed dividend, completed 1% share buyback and narrowing annual net loss have arrived alongside stronger trading...

Roblox (NYSE:RBLX) reported strong fourth quarter results, highlighting solid bookings and active user metrics. The company introduced facial age estimation and more than 145 new safety initiatives across its platform. Management emphasized a focus on leading online safety standards for both younger users and a growing adult audience. Roblox runs a global 3D social and gaming platform where users create, share, and play content built by the community. The latest safety updates sit alongside...

PVH Corp. recently announced a collaboration with OpenAI to co-create custom AI tools across Calvin Klein, Tommy Hilfiger and its broader operating model, and earlier affirmed a quarterly cash dividend of US$0.0375 per share payable on March 25, 2026 to shareholders of record on March 4, 2026. The AI partnership is designed to embed advanced analytics into product design, demand planning, inventory optimization and consumer engagement, potentially reshaping how PVH runs its core fashion and...

In early February 2026, Exact Sciences reported that its Oncotype DX Breast Recurrence Score test has now guided treatment decisions for more than two million early-stage HR+, HER2- breast cancer patients worldwide, supported by over two decades of clinical evidence and broad global adoption. The company highlighted that Oncotype DX remains the only genomic assay proven to be both prognostic and predictive for chemotherapy benefit, with published models suggesting meaningful lifetime cost...

Meritage Homes (MTH) is back in focus after its latest earnings release, which combined lower annual revenue and net income with real estate impairments, flat 2026 revenue guidance, sizable buybacks, and record community growth. See our latest analysis for Meritage Homes. At a share price of $75.91, Meritage Homes has seen stronger recent momentum, with a 7 day share price return of 8.15% and a 90 day share price return of 10.21%. Its 5 year total shareholder return of 83.21% shows how the...

Recent research coverage highlights Excelerate Energy’s history of outperforming earnings estimates, pointing to past quarterly surprises and a current positive Earnings ESP, with the next report scheduled for February 25, 2026. An interesting angle is how the combination of a positive Earnings ESP and a mid-range Zacks Rank is shaping expectations around Excelerate Energy’s ability to outpace consensus forecasts. With this backdrop of anticipated earnings outperformance, we’ll explore what...

Denali Therapeutics (DNLI) has drawn fresh attention after presenting clinical and preclinical data at the 22nd Annual WORLDSymposium, updating investors on its Enzyme Transport Vehicle programs and upcoming regulatory milestones for rare disease candidates. See our latest analysis for Denali Therapeutics. Those WORLDSymposium updates and the recent shareholder and analyst call come after a 90 day share price return of 35.13% and a 30 day share price return of 23.42%. However, the 1 year...

In early February 2026, AGCO Corporation reported fourth-quarter 2025 results with quarterly sales of US$2,920.2 million, a return to net profitability, and full-year 2025 sales of US$10,082 million alongside earnings per share from continuing operations of US$9.75. The company also issued 2026 guidance targeting net sales of US$10.4 billion to US$10.7 billion and earnings per share of about US$5.50 to US$6.00, while showcasing new Fendt and Massey Ferguson innovations such as the Fendt e100...

CNX Resources reported past fourth-quarter 2025 results showing total production volumes of 152.3 Bcfe, average daily production of 1,654.8 MMcfe, revenue of US$610.48 million, and net income of US$196.25 million, alongside increased 2026 production guidance and a larger US$4.45 billion share buyback authorization. The combination of higher volumes, a swing from loss to profit, and a very large expansion of the repurchase program highlights management’s confidence in cash generation and...

Why recent analyst moves matter for Westlake stock Mizuho’s decision to shift Westlake (WLK) from an Outperform rating to Neutral, while other firms keep buy calls in place, has put fresh attention on what current prices already reflect. See our latest analysis for Westlake. The recent analyst debate comes on the heels of strong short term momentum, with a 4.08% 1 day share price return and a 51.19% 90 day share price return, contrasting with a 1 year total shareholder return decline of...

Werner Enterprises (WERN) stock is in focus after the company reported a quarterly loss, missed revenue and earnings expectations, and highlighted pressure from a soft freight market and higher operating costs. See our latest analysis for Werner Enterprises. The weak quarter triggered an 8.21% one day share price decline and a 4.45% seven day share price return, although the 90 day share price return of 40.05% and 1 year total shareholder return of 2.61% point to momentum that has cooled...

Nucor Corporation has reported its fourth-quarter and full-year 2025 results, with annual sales rising to US$32.49 billion while net income eased to US$1.74 billion, and quarterly earnings improving year over year. Alongside completing a multiyear US$3.59 billion share repurchase program, Nucor issued guidance pointing to higher first-quarter 2026 earnings across all three operating segments. We’ll now examine how Nucor’s expectation of higher first-quarter 2026 earnings across all segments...

Revolution Medicines recently dosed the first patient in its first-in-human trial of RMC-5127, an open-label study assessing safety, tolerability, pharmacokinetics and early antitumor activity in RAS G12V-mutated solid tumors that have progressed after standard therapies. This marks a key pipeline milestone targeting RAS G12V, the second most common driver of RAS-addicted cancers in the US, affecting roughly 48,000 patients annually. We will now examine how initiating first-in-human testing...

Sonic Automotive, Inc.'s ( NYSE:SAH ) price-to-earnings (or "P/E") ratio of 16.4x might make it look like a buy right...

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...

Why Ribbon Communications is back on investor radar Ribbon Communications (RBBN) has drawn attention after reporting fourth quarter and full year 2025 results alongside fresh 2026 revenue guidance, giving investors updated numbers on profitability and the coming year. The company reported fourth quarter 2025 revenue of US$227.32 million compared with US$251.36 million a year earlier, while net income moved to US$89.07 million from US$6.36 million. Full year revenue was US$844.56 million...

Two Harbors Investment earnings reset draws investor focus Two Harbors Investment (TWO) has come under fresh scrutiny after reporting fourth quarter net income of US$11.72 million and a full year net loss of US$454.3 million, marking a sharp reversal in profitability. See our latest analysis for Two Harbors Investment. The latest results appear to have shifted sentiment, with the share price down 7.54% on the day of the announcement and a 9.73% 30 day share price return. This is in contrast...

Earnings event puts Regal Rexnord in focus Regal Rexnord (RRX) is back on investors’ radar after its latest quarterly earnings, where higher adjusted earnings, net income, and operating margins coincided with strong demand in data center, automation, and aerospace markets. See our latest analysis for Regal Rexnord. The earnings news has gone hand in hand with a sharp re-rating in the share price, with a 1-day share price return of 5.9%, a 30-day share price return of 38.8%, and a 1-year total...